BRPI0606839B8 - Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr) - Google Patents
Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)Info
- Publication number
- BRPI0606839B8 BRPI0606839B8 BRPI0606839A BRPI0606839A BRPI0606839B8 BR PI0606839 B8 BRPI0606839 B8 BR PI0606839B8 BR PI0606839 A BRPI0606839 A BR PI0606839A BR PI0606839 A BRPI0606839 A BR PI0606839A BR PI0606839 B8 BRPI0606839 B8 BR PI0606839B8
- Authority
- BR
- Brazil
- Prior art keywords
- egfr
- inhibitor
- pharmaceutical composition
- growth factor
- factor receptor
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title abstract 7
- 102000001301 EGF receptor Human genes 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000002427 irreversible effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 239000005411 L01XE02 - Gefitinib Substances 0.000 abstract 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 abstract 3
- 229960001433 erlotinib Drugs 0.000 abstract 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 abstract 3
- 229960002584 gefitinib Drugs 0.000 abstract 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract 3
- NERXPXBELDBEPZ-RMKNXTFCSA-N (e)-n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 NERXPXBELDBEPZ-RMKNXTFCSA-N 0.000 abstract 1
- 239000013038 irreversible inhibitor Substances 0.000 abstract 1
- 229950008835 neratinib Drugs 0.000 abstract 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64948305P | 2005-02-03 | 2005-02-03 | |
US60/649,483 | 2005-02-03 | ||
US67198905P | 2005-04-15 | 2005-04-15 | |
US60/671,989 | 2005-04-15 | ||
PCT/US2006/003717 WO2006084058A2 (en) | 2005-02-03 | 2006-02-02 | Method for treating gefitinib resistant cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0606839A2 BRPI0606839A2 (pt) | 2010-03-09 |
BRPI0606839B1 BRPI0606839B1 (pt) | 2021-11-30 |
BRPI0606839B8 true BRPI0606839B8 (pt) | 2021-12-14 |
Family
ID=36777922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606839A BRPI0606839B8 (pt) | 2005-02-03 | 2006-02-02 | Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr) |
Country Status (28)
Country | Link |
---|---|
US (3) | US10603314B2 (pt) |
EP (1) | EP1848414B1 (pt) |
JP (1) | JP2008528695A (pt) |
KR (1) | KR101313702B1 (pt) |
CN (7) | CN113952338A (pt) |
AT (1) | ATE504299T1 (pt) |
AU (1) | AU2006210572B2 (pt) |
BR (1) | BRPI0606839B8 (pt) |
CA (1) | CA2596714C (pt) |
CY (2) | CY1111676T1 (pt) |
DE (1) | DE602006021142D1 (pt) |
DK (1) | DK1848414T3 (pt) |
ES (1) | ES2364495T3 (pt) |
FR (1) | FR16C1004I1 (pt) |
HK (1) | HK1105285A1 (pt) |
HU (1) | HUS1600033I1 (pt) |
IL (3) | IL184791A (pt) |
LU (1) | LU93160I2 (pt) |
MX (1) | MX2007009317A (pt) |
NI (1) | NI200700185A (pt) |
NO (1) | NO20074366L (pt) |
NZ (1) | NZ556673A (pt) |
PL (1) | PL1848414T3 (pt) |
PT (1) | PT1848414E (pt) |
RU (2) | RU2405566C2 (pt) |
SI (1) | SI1848414T1 (pt) |
WO (1) | WO2006084058A2 (pt) |
ZA (1) | ZA200706804B (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
EP1851339B1 (en) | 2005-02-11 | 2016-05-18 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for detecting a drug resistant egfr mutant |
CA2646257A1 (en) * | 2005-04-14 | 2006-10-26 | Wyeth | Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |
RU2451524C2 (ru) | 2005-11-04 | 2012-05-27 | Вайет | Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272 |
CA2629249C (en) * | 2005-11-11 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
CA2833852C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
KR20090074202A (ko) * | 2006-09-18 | 2009-07-06 | 베링거 인겔하임 인터내셔날 게엠베하 | Egfr 돌연변이를 갖는 암을 치료하는 방법 |
CN101516376A (zh) * | 2006-09-18 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | 用于治疗携带egfr突变的癌症的方法 |
WO2008121467A2 (en) * | 2007-02-28 | 2008-10-09 | Dana-Farber Cancer Institute, Inc. | Combination therapy for treating cancer |
WO2008109361A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc, | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
AU2013203111B2 (en) * | 2007-04-13 | 2015-10-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating cancer resistant to erbb therapeutics |
US8715665B2 (en) * | 2007-04-13 | 2014-05-06 | The General Hospital Corporation | Methods for treating cancer resistant to ErbB therapeutics |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2310011B1 (en) | 2008-06-17 | 2013-07-24 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
KR101434009B1 (ko) | 2008-08-04 | 2014-08-25 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
JP5963672B2 (ja) | 2009-07-06 | 2016-08-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bibw2992、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法 |
CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
WO2011069962A1 (en) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
WO2011079231A1 (en) * | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
BR112012015721A2 (pt) | 2009-12-30 | 2017-09-26 | Avila Therapeutics Inc | modificação covalente de proteínas dirigida por ligante |
NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CN105348266B (zh) | 2011-07-27 | 2018-04-10 | 阿斯利康(瑞典)有限公司 | 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐 |
EP2751285B2 (en) * | 2011-08-31 | 2020-04-01 | Genentech, Inc. | Method for sensitivity testing of a tumour for a egfr kinase inhibitor |
US20150064200A1 (en) * | 2012-04-04 | 2015-03-05 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for 6-phosphogluconate dehydrogenase (6-pgd) as a target for lung cancer therapy |
CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
US20140308274A1 (en) * | 2013-03-15 | 2014-10-16 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors |
KR101384686B1 (ko) | 2013-05-28 | 2014-04-21 | 주식회사 바이오인프라 | Egfr 표적 치료제에 대한 폐암의 치료 반응성을 예측하는 방법 |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
KR101751371B1 (ko) | 2014-06-25 | 2017-06-27 | 연세대학교 원주산학협력단 | 3,4,5-트리하이드록시벤조산, 이의 유도체 또는 이의 염을 유효성분으로 포함하는 수용체 티로신 키나아제 저해제 내성 항암제 조성물 |
WO2016029175A1 (en) * | 2014-08-21 | 2016-02-25 | Pharmacyclics Llc | Methods for treating egfr mutant disorders |
CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
US9364469B1 (en) * | 2015-08-26 | 2016-06-14 | Macau University Of Science And Technology | Identification of a new AMPK activator for treatment of lung cancer |
GB201516905D0 (en) * | 2015-09-24 | 2015-11-11 | Stratified Medical Ltd | Treatment of Neurodegenerative diseases |
WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
US20210054463A1 (en) * | 2017-02-26 | 2021-02-25 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Frequent egfr and ntrk somatic mutations in colorectal cancer (crc) with microsatellite instability (msi) |
CN111867586A (zh) * | 2018-03-13 | 2020-10-30 | 得克萨斯州大学系统董事会 | 用于治疗具有egfr激活突变的癌症的方法 |
US20210190761A1 (en) * | 2019-12-19 | 2021-06-24 | Johnson & Johnson Consumer Inc. | Method for Evaluating the Efficacy of a Composition in Reducing the Effects of Cancer Therapeutics on Skin |
US20230248671A1 (en) * | 2020-07-10 | 2023-08-10 | Chang Gung Memorial Hospital, Linkou | Use of beta-1 adrenergic receptor antagonist for preparing compositions for reducing epithelial cell damage induced by epidermal growth factor receptor inhibitors and inhibiting cancer cells |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
CN113234832B (zh) * | 2021-06-30 | 2022-06-03 | 深圳市狂风生命科技有限公司 | 人类egfr基因错义突变分子标志物及其在预测靶向抑制剂抗药性中的应用 |
CN114569617B (zh) * | 2022-05-06 | 2022-07-29 | 中国农业大学 | 甲基硒酸作为吉非替尼治疗吉非替尼耐药的非小细胞肺癌增敏剂的新用途 |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
CA2045231A1 (en) * | 1990-07-19 | 1992-01-20 | Victor Ling | Cell membrane glycoprotein correlated with resistance to platinum-containing antineoplastic agents |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
TW254946B (pt) | 1992-12-18 | 1995-08-21 | Hoffmann La Roche | |
AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
TW398975B (en) | 1994-07-22 | 2000-07-21 | Lilly Co Eli | Pharmaceutical composition for inhibiting bone loss |
US5476932A (en) | 1994-08-26 | 1995-12-19 | Hoffmann-La Roche Inc. | Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
JP3437685B2 (ja) | 1995-09-12 | 2003-08-18 | 株式会社東芝 | 交直変換装置の制御保護システム |
DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6426383B1 (en) * | 1997-05-28 | 2002-07-30 | Nalco Chemical Company | Preparation of water soluble polymer dispersions from vinylamide monomers |
US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
KR100705142B1 (ko) | 1998-09-29 | 2007-04-06 | 와이어쓰 홀딩스 코포레이션 | 단백질 티로신 키나제 억제제로서 치환 3-시아노퀴놀린 |
US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
AU2930501A (en) | 2000-01-07 | 2001-07-24 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
US6384051B1 (en) | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
JP2004525950A (ja) | 2001-04-06 | 2004-08-26 | ワイス | ラパマイシンとゲムシタビンまたはフルオロウラシルなどの、抗腫瘍剤の組み合わせ |
TWI233359B (en) | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
TWI296196B (en) | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
KR100875611B1 (ko) | 2001-06-01 | 2008-12-24 | 와이어쓰 | mTOR 억제제 및 항신생물성 알킬화제를 포함하는 제품 |
ZA200603888B (en) | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
AU2002345670A1 (en) | 2001-06-14 | 2003-01-02 | The Regents Of The University Of California | Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571 |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
DE60221886D1 (de) | 2001-11-27 | 2007-09-27 | Wyeth Corp | 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen |
JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
WO2003106622A2 (en) | 2002-05-30 | 2003-12-24 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
ES2279120T3 (es) * | 2002-06-05 | 2007-08-16 | Cedars-Sinai Medical Center | Gefitinib (iressa) para el tratamiento del cancer. |
US20060094674A1 (en) | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
WO2004010937A2 (en) * | 2002-07-26 | 2004-02-05 | Advanced Research & Technology Institute At Indiana University | Method of treating cancer |
AU2003258061A1 (en) * | 2002-08-02 | 2004-02-23 | Salmedix, Inc. | Therapeutic inhibitionof protein kinases in cancer cells |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
EP1594504A4 (en) * | 2003-01-23 | 2008-12-17 | T K Signal Ltd | NEW IRREVERSIBLE EGF RECEPTOR TYROSINE KINASE INHIBITORS AND THEIR USES FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES |
CN1437942A (zh) | 2003-02-08 | 2003-08-27 | 杭州华卫制药技术开发有限公司 | 注射用长春瑞滨粉针剂及制备方法 |
UA83484C2 (uk) | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
CA2519338A1 (en) | 2003-04-22 | 2004-11-04 | Wyeth | Antineoplastic combinations |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
KR101139557B1 (ko) | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
RU2006106267A (ru) | 2003-08-01 | 2006-07-27 | Уайт Холдингз Корпорейшн (Us) | Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака |
AU2004267061A1 (en) | 2003-08-19 | 2005-03-03 | Wyeth Holdings Corporation | Process for the preparation of 4-amino-3-quinolinecarbonitriles |
AU2003304497B2 (en) | 2003-09-15 | 2010-06-24 | Wyeth Llc | Substituted quinolines as protein tyrosine kinase enzyme inhibitors |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
WO2005049021A1 (en) | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
WO2005044091A2 (en) | 2003-11-05 | 2005-05-19 | Board Of Regents, The University Of Texas System | Diagnostic and therapeutic methods and compositions involving pten and breast cancer |
AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
EP1694330A4 (en) | 2003-12-04 | 2009-06-24 | Amr Technology Inc | DERIVATIVES OF VINORELBINE |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
AR047988A1 (es) | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
ES2425749T3 (es) | 2004-03-31 | 2013-10-17 | The General Hospital Corporation | Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico |
ES2338556T3 (es) | 2004-05-28 | 2010-05-10 | Hetero Drugs Limited | Sintesis estereoselectiva novedosa de sulfoxidos de benzimidazol. |
EP2592155B2 (en) * | 2004-06-04 | 2019-09-11 | Genentech, Inc. | EGFR mutations |
AU2005263972A1 (en) | 2004-07-23 | 2006-01-26 | Astrazeneca Ab | Method of predicting the responsiveness of a tumor to erbB receptor drugs |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
TW200616612A (en) | 2004-10-08 | 2006-06-01 | Wyeth Corp | Method for the teatment of polycystic kidney disease field of invention |
WO2006044453A1 (en) | 2004-10-13 | 2006-04-27 | Wyeth | Analogs of 17-hydroxywortmannin as pi3k inhibitors |
US20080254497A1 (en) | 2004-10-15 | 2008-10-16 | Monogram Biosciences, Inc. | Response Predictors for Erbb Pathway-Specific Drugs |
US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
WO2006085168A2 (en) | 2005-01-07 | 2006-08-17 | Ranbaxy Laboratories Limited | Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
WO2006081985A1 (en) | 2005-02-04 | 2006-08-10 | F. Hoffmann-La Roche Ag | Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor |
JP2008535477A (ja) | 2005-02-24 | 2008-09-04 | アムジエン・インコーポレーテツド | 上皮成長因子受容体変異 |
SI1859793T1 (sl) | 2005-02-28 | 2011-08-31 | Eisai R&D Man Co Ltd | Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka |
WO2006093353A1 (ja) | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
ES2441019T3 (es) | 2005-03-09 | 2014-01-31 | Abbott Laboratories | Métodos de diagnóstico para identificar pacientes candidatos para el tratamiento con trastuzumab |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US20060235006A1 (en) | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
CA2646257A1 (en) * | 2005-04-14 | 2006-10-26 | Wyeth | Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |
US20110045459A1 (en) | 2005-04-21 | 2011-02-24 | Mischel Paul S | Molecular determinants of EGFR kinase inhibitor response in glioblastoma |
TW200716129A (en) | 2005-04-28 | 2007-05-01 | Wyeth Corp | Micronized tanaproget, compositions, and methods of preparing the same |
KR20070119745A (ko) | 2005-05-12 | 2007-12-20 | 화이자 인코포레이티드 | 수니티닙 말레이트를 사용하는 항암 병행 요법 |
KR20080016671A (ko) | 2005-05-25 | 2008-02-21 | 와이어쓰 | 치환된 3-시아노퀴놀린 및 그것의 중간체를 합성하는 방법 |
RU2007139544A (ru) | 2005-05-25 | 2009-06-27 | Вайет (Us) | Способ получения 3-цианохинолинов и промежуточные соединения, полученные согласно данному способу |
DE102005053679A1 (de) | 2005-06-24 | 2006-12-28 | Bayer Healthcare Ag | Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems |
PE20070192A1 (es) | 2005-07-15 | 2007-03-16 | Wyeth Corp | Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina |
US20100105031A1 (en) | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
BRPI0520530A2 (pt) | 2005-10-05 | 2009-09-29 | Astrazeneca Uk Ltd | método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb |
WO2007050495A2 (en) | 2005-10-26 | 2007-05-03 | Children's Medical Center Corporation | Method to prognose response to anti-egfr therapeutics |
RU2451524C2 (ru) | 2005-11-04 | 2012-05-27 | Вайет | Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272 |
PE20071042A1 (es) | 2005-11-04 | 2007-10-12 | Wyeth Corp | Producto farmaceutico que comprende temsirolimus y malato de sunitinib |
CA2629249C (en) | 2005-11-11 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
ATE450266T1 (de) | 2005-11-24 | 2009-12-15 | Aicuris Gmbh & Co Kg | Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs |
JP2007145745A (ja) | 2005-11-25 | 2007-06-14 | Osaka Univ | 変異型EGFR下流シグナルを抑制するSrcファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用 |
EP1965770A2 (en) | 2005-12-22 | 2008-09-10 | Wyeth a Corporation of the State of Delaware | Oral formulations comprising tigecycline |
WO2007095038A2 (en) | 2006-02-09 | 2007-08-23 | Novartis Ag | Mutations and polymorphisms of erbb2 |
AU2007235976A1 (en) | 2006-04-07 | 2007-10-18 | Novartis Ag | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
TW200806282A (en) | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
US20100113299A1 (en) | 2008-10-14 | 2010-05-06 | Von Hoff Daniel D | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type |
BRPI0711011A2 (pt) | 2006-05-18 | 2011-08-23 | Molecular Profiling Inst Inc | método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença |
TW200808728A (en) | 2006-05-23 | 2008-02-16 | Wyeth Corp | Method of preparing 4-halogenated quinoline intermediates |
CA2655997A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
KR20090074202A (ko) | 2006-09-18 | 2009-07-06 | 베링거 인겔하임 인터내셔날 게엠베하 | Egfr 돌연변이를 갖는 암을 치료하는 방법 |
JP2010504974A (ja) | 2006-09-28 | 2010-02-18 | フォリカ,インコーポレーテッド | 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物 |
EP2073823A1 (en) | 2006-10-13 | 2009-07-01 | Medigene AG | Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer |
EP2104501B1 (en) | 2006-12-13 | 2014-03-12 | Merck Sharp & Dohme Corp. | Methods of cancer treatment with igf1r inhibitors |
US20100143340A1 (en) | 2006-12-13 | 2010-06-10 | Schering Corporation | Methods and compositions for treating cancer |
ES2703723T3 (es) | 2006-12-14 | 2019-03-12 | Exelixis Inc | Métodos para usar inhibidores de MEK |
WO2008076143A1 (en) | 2006-12-18 | 2008-06-26 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
EP2815750A1 (en) | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
CL2008000095A1 (es) | 2007-01-12 | 2008-05-16 | Wyeth Corp | Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen |
MX2009007987A (es) | 2007-01-25 | 2010-03-01 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
CA2677193C (en) | 2007-02-01 | 2015-06-30 | Takeda Pharmaceutical Company Limited | Tablet preparation without causing a tableting trouble |
WO2008121467A2 (en) | 2007-02-28 | 2008-10-09 | Dana-Farber Cancer Institute, Inc. | Combination therapy for treating cancer |
GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
EP1978106A1 (en) | 2007-04-07 | 2008-10-08 | Universitätsklinikum Hamburg-Eppendorf | Detection of ESR1 amplification in endometrium cancer and ovary cancer |
US8715665B2 (en) | 2007-04-13 | 2014-05-06 | The General Hospital Corporation | Methods for treating cancer resistant to ErbB therapeutics |
EP2145188A4 (en) | 2007-04-19 | 2010-06-30 | Wellstat Biologics Corp | DETECTION OF HER2 / NEU PROTEIN FROM UNISISIONED CIRCULATING CANCER CELLS AND TREATMENT |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
US20110014117A1 (en) | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
CA2736564A1 (en) | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
JP2010540459A (ja) | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ,インク. | Cox‐2阻害薬及びegfr[erbb1]とher‐2[erbb2]の二重阻害薬を用いた癌を治療するための併用療法 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
CA2702637A1 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
EP2214770A4 (en) | 2007-11-05 | 2011-01-05 | Puretech Ventures | METHODS, KITS AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS |
CN101185633A (zh) | 2007-12-14 | 2008-05-28 | 山东蓝金生物工程有限公司 | 一种治疗实体肿瘤的尼拉替尼缓释植入剂 |
CA2709827A1 (en) | 2007-12-18 | 2009-06-25 | Schering Corporation | Biomarkers for sensitivity to anti-igf1r therapy |
US20100297118A1 (en) | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
WO2009105234A2 (en) | 2008-02-19 | 2009-08-27 | Combinatorx, Incorporated | Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein |
ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
WO2009111073A2 (en) | 2008-03-06 | 2009-09-11 | Odyssey Thera, Inc. | High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders |
EP2259797A2 (en) | 2008-03-25 | 2010-12-15 | Schering Corporation | Methods for treating or preventing colorectal cancer |
US8741861B2 (en) | 2008-03-27 | 2014-06-03 | Vascular Biosciences | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
WO2009146034A2 (en) | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
US20110182888A1 (en) | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
EA022588B1 (ru) | 2008-04-18 | 2016-01-29 | Ритэ Фамэсутикл, Инк. | Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце |
WO2009129548A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
US8124799B2 (en) | 2008-04-18 | 2012-02-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
CN103588678A (zh) | 2008-04-18 | 2014-02-19 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
EP2282739A2 (en) | 2008-05-05 | 2011-02-16 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
EP2310011B1 (en) | 2008-06-17 | 2013-07-24 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
US8314137B2 (en) | 2008-07-22 | 2012-11-20 | Trustess Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
KR101434009B1 (ko) | 2008-08-04 | 2014-08-25 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
US20100069340A1 (en) | 2008-09-11 | 2010-03-18 | Wyeth | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
WO2010048477A2 (en) | 2008-10-24 | 2010-04-29 | Wyeth Llc | Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates |
BRPI0921407A2 (pt) | 2008-11-07 | 2019-09-24 | Enzo Pharmaceuticals Inc | terapia de combinação seletiva de erbb-3 (her3) |
WO2010085845A1 (en) | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
US20120130144A1 (en) | 2009-02-04 | 2012-05-24 | Bipar Sciences, Inc. | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor |
WO2010098627A2 (ko) | 2009-02-27 | 2010-09-02 | 한올바이오파마주식회사 | 약제학적 제제 |
CA2754808C (en) | 2009-03-11 | 2019-01-08 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
AR076053A1 (es) | 2009-04-14 | 2011-05-18 | Schering Corp | Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor |
WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
SG177309A1 (en) | 2009-07-02 | 2012-02-28 | Wyeth Llc | 3-cyanoquinoline tablet formulations and uses thereof |
WO2011008053A2 (ko) | 2009-07-17 | 2011-01-20 | 한올바이오파마주식회사 | N,n-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 |
KR20110007985A (ko) | 2009-07-17 | 2011-01-25 | 한올바이오파마주식회사 | N,n―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 |
WO2011025267A2 (ko) | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
KR101211227B1 (ko) | 2009-08-25 | 2012-12-11 | 한올바이오파마주식회사 | 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
KR101190953B1 (ko) | 2009-08-25 | 2012-10-12 | 한올바이오파마주식회사 | 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
US20110055838A1 (en) | 2009-08-28 | 2011-03-03 | Moyes William A | Optimized thread scheduling via hardware performance monitoring |
WO2011038467A1 (en) | 2009-10-01 | 2011-04-07 | Csl Limited | Method of treatment of philadelphia chromosome positive leukaemia |
AU2010315362B2 (en) | 2009-11-09 | 2015-01-22 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
RS59599B2 (sr) | 2009-11-09 | 2023-03-31 | Wyeth Llc | Formulacije tableta neratinib maleata |
PT2719708T (pt) | 2009-11-13 | 2018-01-16 | Daiichi Sankyo Europe Gmbh | Material e métodos para tratamento ou prevenção de doenças associadas a her-3 |
WO2011069962A1 (en) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
WO2011070499A1 (en) | 2009-12-11 | 2011-06-16 | Wyeth Llc | Phosphatidylinositol-3-kinase pathway biomarkers |
WO2011087926A1 (en) | 2010-01-13 | 2011-07-21 | Wyeth Llc | A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR |
-
2006
- 2006-02-02 DE DE602006021142T patent/DE602006021142D1/de active Active
- 2006-02-02 SI SI200631028T patent/SI1848414T1/sl unknown
- 2006-02-02 RU RU2007132902/14A patent/RU2405566C2/ru active
- 2006-02-02 CN CN202111227670.3A patent/CN113952338A/zh active Pending
- 2006-02-02 PL PL06720163T patent/PL1848414T3/pl unknown
- 2006-02-02 CN CN202111229046.7A patent/CN113952459A/zh active Pending
- 2006-02-02 WO PCT/US2006/003717 patent/WO2006084058A2/en active Application Filing
- 2006-02-02 PT PT06720163T patent/PT1848414E/pt unknown
- 2006-02-02 ZA ZA200706804A patent/ZA200706804B/xx unknown
- 2006-02-02 MX MX2007009317A patent/MX2007009317A/es active IP Right Grant
- 2006-02-02 BR BRPI0606839A patent/BRPI0606839B8/pt active IP Right Grant
- 2006-02-02 AT AT06720163T patent/ATE504299T1/de active
- 2006-02-02 US US11/883,474 patent/US10603314B2/en active Active
- 2006-02-02 ES ES06720163T patent/ES2364495T3/es active Active
- 2006-02-02 JP JP2007554212A patent/JP2008528695A/ja not_active Withdrawn
- 2006-02-02 CA CA2596714A patent/CA2596714C/en active Active
- 2006-02-02 NZ NZ556673A patent/NZ556673A/en unknown
- 2006-02-02 AU AU2006210572A patent/AU2006210572B2/en active Active
- 2006-02-02 DK DK06720163.2T patent/DK1848414T3/da active
- 2006-02-02 CN CN2006800110039A patent/CN101155579B/zh active Active
- 2006-02-02 CN CN201810778846.6A patent/CN108743588A/zh active Pending
- 2006-02-02 CN CN2012103281332A patent/CN102886045A/zh active Pending
- 2006-02-02 CN CN202111227643.6A patent/CN113975393A/zh active Pending
- 2006-02-02 KR KR1020077017963A patent/KR101313702B1/ko active IP Right Grant
- 2006-02-02 RU RU2007132902/14D patent/RU2405566C9/ru active
- 2006-02-02 CN CN201810224246.5A patent/CN108421044A/zh active Pending
- 2006-02-02 EP EP06720163A patent/EP1848414B1/en active Active
-
2007
- 2007-07-23 IL IL184791A patent/IL184791A/en not_active IP Right Cessation
- 2007-07-26 NI NI200700185A patent/NI200700185A/es unknown
- 2007-08-27 NO NO20074366A patent/NO20074366L/no not_active Application Discontinuation
- 2007-12-17 HK HK07113693.6A patent/HK1105285A1/xx unknown
-
2011
- 2011-07-05 CY CY20111100647T patent/CY1111676T1/el unknown
-
2016
- 2016-07-11 US US15/207,349 patent/US10596162B2/en active Active
- 2016-07-26 LU LU93160C patent/LU93160I2/fr unknown
- 2016-07-26 FR FR16C1004C patent/FR16C1004I1/fr active Active
- 2016-07-26 HU HUS1600033C patent/HUS1600033I1/hu unknown
- 2016-07-27 CY CY2016026C patent/CY2016026I2/el unknown
- 2016-08-08 IL IL247165A patent/IL247165A0/en unknown
-
2018
- 2018-05-31 IL IL259741A patent/IL259741A/en unknown
-
2022
- 2022-08-17 US US17/820,519 patent/US20230226039A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606839B8 (pt) | Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr) | |
BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
BR112012010027A2 (pt) | dispositivo para uso pessoal em uma fototerapia | |
GT200600254A (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
BRPI0513944A (pt) | forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
ECSP045474A (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 | |
CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
BR112017012287A2 (pt) | uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr | |
BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
AR055029A1 (es) | Uso de inhibidores de tirosina quinasa para el tratamiento de rinosinusitis cronica | |
BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
BRPI0804070A2 (pt) | usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto | |
CL2008000150A1 (es) | Formas cristalinas de compuestos derivados de n-(2-amino fenil)-4-pirazol-1-il metil benzamida; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico que comprende a dichos compuestos; y su uso para tratar cancer, psoriasis, ar | |
BR112013009143A2 (pt) | método in vitro, uso e invenção | |
BR112022007632A2 (pt) | Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: THE GENERAL HOSPITAL CORPORATION (US) ; WYETH LLC (US) |
|
B25G | Requested change of headquarter approved |
Owner name: THE GENERAL HOSPITAL CORPORATION (US) ; WYETH LLC (US) |
|
B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2656 DE 30/11/2021 QUANTO AOS DESENHOS. |